Skip to content

Efficacy and Safety Evaluation of Prebiotics Combined With Quadruple Probiotics in Improving Functional Constipation.

Efficacy and Safety Evaluation of Prebiotics Combined With Quadruple Probiotics in Improving Functional Constipation: a Prospective Randomized Controlled Open-label Study

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06277505
Enrollment
60
Registered
2024-02-26
Start date
2024-05-01
Completion date
2025-06-01
Last updated
2024-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Constipation

Keywords

prebiotics, probiotics, functional constipation, Randomized Controlled Trial

Brief summary

In this study, we will evaluate the efficacy of prebiotics combined with quadruple probiotics in the treatment of functional constipation through an open RCT study. The experimental group received lifestyle guidance and combined intervention of prebiotics and quadruple probiotics at the same time. The patients took the combination of prebiotics and probiotics twice a day during the treatment period. The control group received only lifestyle instruction. At the same time, to evaluate the safety of probiotics combined with quadruple probiotics in the treatment of functional constipation, and provide a new treatment plan for clinical treatment of functional constipation.

Detailed description

The purpose of this study is to analyze the intestinal microecology of patients with functional constipation before and after treatment through intestinal microecological intervention, mainly using the combination of probiotics and prebiotics. We will record the patient's stool diary, including bowel movements, stool quality, bowel time, defecation difficulty, emptying sensation, manual operation and medication. At the same time, we will use the Bristol Fecal Traits Scale (BSFS) and the Constipation Patient Self-Rating Scale (PAC-SYM) and Constipation Patient Quality of Life Scale (PAC-QOL) scores completed weekly. In addition, we will monitor indicators of inflammation (IL-1β, IL-6, TNF-alpha) and intestinal barrier function (LPS), neurotransmitter (serotonin, acetylcholine)) to assess constipation improvement in patients with functional constipation.

Interventions

COMBINATION_PRODUCTTake prebiotics and probiotics

Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise

lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise

Sponsors

The First Affiliated Hospital of Xiamen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Age: between 18 and 60 years old 2. Functional constipation was diagnosed using Rome IV criteria. 3. No other relevant medications that may affect the gut microbiota before the start of the experiment 4. Ability to participate 5. Consent to participate in the study

Exclusion criteria

1. Organic constipation (such as intestinal obstruction, bowel cancer, etc.) 2. Outlet obstructive constipation 3. Previous abdominal, rectal, or perianal surgery except cholecystectomy, appendectomy, tubal ligation, and cesarean section 4. Patients with constipation-oriented irritable bowel syndrome (IBS-C) or functional abdominal pain syndrome who meet Rome IV criteria 5. a serious mental illness or any medical condition related to it 6. Diseases of the small or large intestine, such as ulcerative colitis and Crohn's disease 7. There are serious important organs such as respiratory, heart, liver, kidney and other functional insufficiency 8. Use probiotics, prebiotics and/or Biostime within 1 month

Design outcomes

Primary

MeasureTime frameDescription
Change in the number of fully autonomous bowel movements per week at the end of treatmentA month after treatmentChange in the number of fully autonomous bowel movements per week at the end of treatment

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026